These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11041854)

  • 21. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors.
    Lee JC; Yu MC; Lien TW; Chang CF; Hsu JT
    Assay Drug Dev Technol; 2005 Aug; 3(4):385-92. PubMed ID: 16180993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease.
    Zhang R; Durkin JP; Windsor WT
    Bioorg Med Chem Lett; 2002 Apr; 12(7):1005-8. PubMed ID: 11909704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The competitive binding between inhibitors and substrates of HCV NS3/4A protease: a general mechanism of drug resistance.
    Guan Y; Sun H; Li Y; Pan P; Li D; Hou T
    Antiviral Res; 2014 Mar; 103():60-70. PubMed ID: 24462696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Probing the substrate specificity of the dengue virus type 2 NS3 serine protease by using internally quenched fluorescent peptides.
    Niyomrattanakit P; Yahorava S; Mutule I; Mutulis F; Petrovska R; Prusis P; Katzenmeier G; Wikberg JE
    Biochem J; 2006 Jul; 397(1):203-11. PubMed ID: 16489931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
    Perni RB; Pitlik J; Britt SD; Court JJ; Courtney LF; Deininger DD; Farmer LJ; Gates CA; Harbeson SL; Levin RB; Lin C; Lin K; Moon YC; Luong YP; O'Malley ET; Rao BG; Thomson JA; Tung RD; Van Drie JH; Wei Y
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1441-6. PubMed ID: 15006379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease.
    Tran HTL; Morikawa K; Anggakusuma ; Zibi R; Thi VLD; Penin F; Heim MH; Quadroni M; Pietschmann T; Gouttenoire J; Moradpour D
    PLoS One; 2020; 15(7):e0236447. PubMed ID: 32697788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease.
    Slater MJ; Andrews DM; Baker G; Bethell SS; Carey S; Chaignot H; Clarke B; Coomber B; Ellis M; Good A; Gray N; Hardy G; Jones P; Mills G; Robinson E
    Bioorg Med Chem Lett; 2002 Dec; 12(23):3359-62. PubMed ID: 12419361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as hepatitis C virus NS3-4A serine protease inhibitors: synthesis, activity, and X-ray crystal structure of an enzyme inhibitor complex.
    Arasappan A; Njoroge FG; Parekh TN; Yang X; Pichardo J; Butkiewicz N; Prongay A; Yao N; Girijavallabhan V
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5751-5. PubMed ID: 15501035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel inhibitors of hepatitis C NS3-NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid.
    Venkatraman S; Njoroge FG; Wu W; Girijavallabhan V; Prongay AJ; Butkiewicz N; Pichardo J
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1628-32. PubMed ID: 16413182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease.
    Sheng XC; Appleby T; Butler T; Cai R; Chen X; Cho A; Clarke MO; Cottell J; Delaney WE; Doerffler E; Link J; Ji M; Pakdaman R; Pyun HJ; Wu Q; Xu J; Kim CU
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2629-34. PubMed ID: 22366653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
    Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
    Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.
    Llinàs-Brunet M; Bailey M; Déziel R; Fazal G; Gorys V; Goulet S; Halmos T; Maurice R; Poirier M; Poupart MA; Rancourt J; Thibeault D; Wernic D; Lamarre D
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2719-24. PubMed ID: 9873610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors.
    Llinàs-Brunet M; Bailey M; Fazal G; Ghiro E; Gorys V; Goulet S; Halmos T; Maurice R; Poirier M; Poupart MA; Rancourt J; Thibeault D; Wernic D; Lamarre D
    Bioorg Med Chem Lett; 2000 Oct; 10(20):2267-70. PubMed ID: 11055335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
    McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
    J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isosorbide-based peptidomimetics as inhibitors of hepatitis C virus serine protease.
    Portela AC; Barros TG; Lima CHDS; Dias LRS; Azevedo PHRA; Dantas ASCL; Mohana-Borges R; Ventura GT; Pinheiro S; Muri EMF
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3661-3665. PubMed ID: 28729054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.
    McCauley JA; McIntyre CJ; Rudd MT; Nguyen KT; Romano JJ; Butcher JW; Gilbert KF; Bush KJ; Holloway MK; Swestock J; Wan BL; Carroll SS; DiMuzio JM; Graham DJ; Ludmerer SW; Mao SS; Stahlhut MW; Fandozzi CM; Trainor N; Olsen DB; Vacca JP; Liverton NJ
    J Med Chem; 2010 Mar; 53(6):2443-63. PubMed ID: 20163176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320.
    Parsy CC; Alexandre FR; Bidau V; Bonnaterre F; Brandt G; Caillet C; Cappelle S; Chaves D; Convard T; Derock M; Gloux D; Griffon Y; Lallos LB; Leroy F; Liuzzi M; Loi AG; Moulat L; Chiara M; Rahali H; Roques V; Rosinovsky E; Savin S; Seifer M; Standring D; Surleraux D
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5427-36. PubMed ID: 26410074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease.
    Parsy C; Alexandre FR; Brandt G; Caillet C; Cappelle S; Chaves D; Convard T; Derock M; Gloux D; Griffon Y; Lallos L; Leroy F; Liuzzi M; Loi AG; Moulat L; Musiu C; Rahali H; Roques V; Seifer M; Standring D; Surleraux D
    Bioorg Med Chem Lett; 2014 Sep; 24(18):4444-4449. PubMed ID: 25155387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Establishment and application of high throughput screening model for hepatitis C virus NS3-4A protease inhibitors in vitro.
    Jian-rui L; Yan-bin W; Shu-yi S; Hong-shan C; Jian-dong J; Zong-gen B
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):98-101. PubMed ID: 21375947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.